All In Biotech

Drug Trial Radar · NCT06918808

DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease

A Phase 2a Study of Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product (DB-3Q) in Patients With Perianal Fistulizing Crohn's Disease

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

May 19, 2025

Primary completion

Jul 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Direct Biologics, LLCIndustry
Sponsor type
Industry
First posted
Apr 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, randomized, placebo-controlled, sequential cohort, ascending dose clinical trial to evaluate the safety and determine the efficacy of ascending doses of DB-3Q for the treatment of Perianal Fistulizing Crohn's Disease.

Conditions

  • Perianal Fistula Due to Crohn's Disease

Interventions

  • DB-3QBiological

    DB-3Q (IMP) is the frozen liquid formulation of acellular secretome proteins and extracellular vesicles isolated from human bmMSC and processed under current Good Manufacturing Process standards.

  • PlaceboBiological

    0.9% NaCl

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Combined RemissionTime frame: 24 Weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Direct Biologics Investigational Site

    Aurora, Colorado · Recruiting

  • Direct Biologics Investigational Site

    St Louis, Missouri · Recruiting

  • Columbia University Irving Medical Center/NYPH

    New York, New York · Recruiting

  • Direct Biologics Investigational Site

    Philadelphia, Pennsylvania · Recruiting

  • Direct Biologics Investigational Site

    Nashville, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.